Biosig Technologies Inc

BioSig Technologies, Inc. is a medical technology company, which engages in the development of a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of electrocardiographic and intra-cardiac signals. Its product PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intra-cardiac signals for patients undergoing electrophysiology procedures. The company was founded by Kenneth L. Londoner on February 24, 2009 and is headquartered in Westport. CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioSig Technologies Inc (NASDAQ:BSGM) has seen its PURE EP System featured in the new edition of leading electrophysiology trade publication, EP Lab Digest. This is the second time that the computerized electrophysiology system has been highlighted in EP Lab Digest in 2021, having been mentioned in a January editorial by EP Lab's editor-in-chief Bradley Knight.

BioSig Technologies sees its PURE EP System highlighted in new feature article in EP Lab Digest

Westport, CT, April 08, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the PURE EP™ System was highlighted in a feature interview for the April issue of EP Lab Digest, a leading industry publication for electrophysiology professionals.

EP Lab Digest Features Physician Experience with BioSig's Cardiac Signal Acquisition Technology

BioSig Technologies, Inc. (NASDAQ:BSGM) has announced that a top-rated leading hospital system has purchased the company's PURE EP systems for multiple campuses in its national network. “We are pleased to expand our commercial installations across this most important healthcare system in multiple states.

BioSig Technologies says top-rated leading hospital system has purchased its PURE EP systems for multiple campuses in its national network

Westport, CT, April 06, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that a top rated leading hospital system purchased PURE EP™ systems for multiple campuses in their national network.

BioSig lands Commercial Sales to Leading Hospital System

Westport, CT, April 05, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Ken Londoner, CEO of BioSig Technologies, will provide a corporate overview and business update at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12th, 2021 at 3 PM ET.

BioSig Technologies, Inc. to Present at the 20th Annual Needham Virtual Healthcare Conference

BioSig Technologies Inc (NASDAQ:BSGM) said that US Patent Office has allowed a utility patent covering its PURE EP noise-filtering technology. The medical technology firm, which specializes in commercializing a signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, said the patent describes and claims systems and methods for filtering noise during a quiet period.

BioSig Technologies awarded US patent claims for noise-filtering methods of signal processing technology

Westport, CT, March 30, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the U.S. Patent Office had allowed a utility patent covering its PURE EP™ noise-filtering technology. The recently allowed patent application number 17/082,564 entitled “SYSTEMS AND METHODS FOR PERFORMING ELECTROPHYSIOLOGY (EP) SIGNAL PROCESSING " was filed on October 28, 2020. The patent describes and claims systems and methods for filtering noise (e.g., a cardiac signal) during a quiet period. In particular, this patent involves filtering out harmonics and noise from an input cardiac signal.

BioSig Awarded U.S. Patent Claims for the Noise-Filtering Methods for its Signal Processing Technology

BioSig Technologies Inc (NASDAQ:BSGM) founder, Chairman, and CEO Kenneth L. Londoner told investors on Monday that the commercial adoption of the company's first product called the PURE EP, which measures electrocardiographic signals, is “gaining momentum.

BioSig CEO says PURE EP System is “gaining momentum” as it adds new healthcare facilities

Westport, CT, March 29, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company had issued a Letter to Shareholders providing highlights on the Company's recent developments and updates.

BioSig Issues Shareholder Letter with Corporate Update on Recent Achievements and Anticipated Milestones for 2021

The stock price of BioSig Technologies Inc (NASDAQ: BSGM) increased by over 5% pre-market. This is why it happened.

BSGM Stock Price Increases Over 5% Pre-Market: Why It Happened

Westport, CT, March 10, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company has been invited to attend the Oppenheimer 31st Annual Healthcare Conference on Thursday, March 18, 2021. Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, will be participating in a virtual fireside chat at 8:00 AM ET. Mr. Londoner will also be available for investor meetings.

BioSig CEO Kenneth L. Londoner to Present at the Oppenheimer 31st Annual Healthcare Conference

Westport, CT, March 09, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it will present at the 33rd Annual Virtual ROTH Conference, being held on March 15-17, 2021. Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc. will deliver a Company overview and provide updates on recent progress. Mr. Londoner will also be available for investor meetings.

BioSig CEO Kenneth L. Londoner to Present at the 33rd Annual Virtual ROTH Conference

BioSig Technologies, Inc. (NASDAQ:BSGM), has said the US Patent Office has allowed a utility patent that its majority-owned subsidiary NeuroClear Technologies, Inc. had exclusively licensed from the Mayo Foundation for Medical Education and Research.

BioSig Technologies says US Patent Office allows utility patent that its subsidiary NeuroClear had exclusively licensed from the Mayo Foundation

Westport, CT, March 04, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the U.S. Patent Office had allowed a utility patent that its majority-owned subsidiary NeuroClear Technologies, Inc. has exclusively licensed from the Mayo Foundation for Medical Education and Research.

BioSig Awarded U.S. Patent Claims for its NeuroClear™ Subsidiary

BioSig Technologies, Inc. (NASDAQ:BSGM) announced Tuesday that it has appointed Brenda Castrodad to lead its Human Resources department. The medical technology company seasoned executive noted that Castrodad brings a wealth of experience in leading organizational development in start-ups and Fortune 500 companies within the life sciences sector.

BioSig Technologies appoints Brenda Castrodad to lead its Human Resources department

Seasoned medtech executive to scale up the Company's organizational development upon the increase in demand for the evaluative installations of the PURE EP System™ Seasoned medtech executive to scale up the Company's organizational development upon the increase in demand for the evaluative installations of the PURE EP System™

BioSig Appoints Brenda Castrodad to Lead Human Resources

BioSig Technologies, Inc. (NASDAQ:BSGM) said it has entered into three new evaluation agreements for the PURE EP System, its novel electrophysiology (EP) signal acquisition and analysis technology. The group said new clinical sites due to receive BioSig's PURE EP System include New York-Presbyterian/Weill Cornell Medical Center, Michigan Medicine–University Hospital - two centers that account for two of the largest EP programs in the country - and Houston Methodist Hospital.

BioSig Technologies says it has entered into three new evaluation agreements for its PURE EP System

New 90-day evaluation cycles enable hospitals to more rapidly assess the platform technology while also accelerating BioSig's commercial activities New 90-day evaluation cycles enable hospitals to more rapidly assess the platform technology while also accelerating BioSig's commercial activities

Major Medical Centers Enter into Installation Agreements for Evaluation of BioSig PURE EP™ Systems

Westport, CT, Jan. 27, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it will present at the Virtual Investor Conference Small and Microcap Showcase on February 4, 2021.

BioSig CEO Kenneth L. Londoner to Present at the Virtual Investor Conference Small and Microcap Showcase

PURE EP(tm) System to be highlighted in a Spotlight session by G. Joseph Gallinghouse, M.D., Texas Cardiac Arrhythmia Institute PURE EP(tm) System to be highlighted in a Spotlight session by G. Joseph Gallinghouse, M.D., Texas Cardiac Arrhythmia Institute

BioSig to Present at the 26th Annual International AF Symposium

Westport, CT, Jan. 14, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the PURE EP™ System was featured in the January issue of EP Lab Digest.

BioSig PURE EP System Featured in the Editorial of EP Lab Digest

Industry-leading smart glasses technology expected to enhance the utility of BioSig's PURE EP™ System signal processing platform. Remote servicing intended to enable continued installations, upgrades, and training during COVID-19 travel restrictions and lockdown limitations. Industry-leading smart glasses technology expected to enhance the utility of BioSig's PURE EP™ System signal processing platform. Remote servicing intended to enable continued installations, upgrades, and training during COVID-19 travel restrictions and lockdown limitations.

BioSig Deploys Vuzix M400 Smart Glasses to Offer Remote Servicing Capabilities in Compliance with COVID-19 Travel Restrictions

PURE EP(tm) system evaluation conducted under the leadership of Cardiologists Vinod Chauhan, M.D. and Deepak Gaba, M.D. Memorial Hospital is nationally recognized for its emphasis on innovation. PURE EP(tm) system evaluation conducted under the leadership of Cardiologists Vinod Chauhan, M.D. and Deepak Gaba, M.D. Memorial Hospital is nationally recognized for its emphasis on innovation.

BioSig Conducts First Patient Cases with PURE EP(tm) System at Memorial Hospital of South Bend, Indiana

Westport, CT, Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. will be presenting live to a virtual audience at the Sidoti Winter 2021 Investor Conference on Wednesday, January 13, 2021  at 2:30 PM ET.

BioSig CEO Kenneth L. Londoner to Present at the Sidoti Winter 2021 Investor Conference

NeuroClear is set to commence experiments aimed at developing therapies for autonomic nervous system disease NeuroClear is set to commence experiments aimed at developing therapies for autonomic nervous system disease

News for Biosig Technologies Inc Stock (BSGM)